Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men
This study is ongoing, but not recruiting participants.
Study NCT00131677 Information provided by Centers for Disease Control and Prevention
First Received: August 17, 2005 Last Updated: September 20, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infection
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Daily oral tenofovir
Additional drug interventions recognized in this trial
Tenofovir
Tenofovir disoproxil
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Centers for Disease Control and Prevention
San Francisco Department of Public Health
AIDS Research Consortium of Atlanta
Back to top of Main Content
